Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

Legend Biotech reversed early gains Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Investors Business Daily

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

Investors Business Daily

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmacy pill trial becomes 'business as usual'

More ways of expanding health care are being considered amid a GP shortage, with women to continue being able to access contraceptive pills at NSW chemists.

AAP

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.

StockNews.com

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level

Lantheus stock is approaching a new buy point on the stock market today after finding support at a key level in recent weeks.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Nasal spray flu vaccine approved for home use: Here’s what to know

Vaccine provides an alternative to flu shots administered with needles

The Independent UK

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

Investors Business Daily

Minister vows 'assertive' approach on vape crackdown

While a ban on vape sales is starting to have an effect, Health Minister Mark Butler says further action is needed on stores that are illegally selling them.

AAP

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Investors Business Daily

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Investors Business Daily

Gavi secures 500,000 doses of mpox vaccine for Africa amid outbreak

The Gavi vaccine alliance has reached an agreement with Danish pharmaceutical company Bavarian Nordic to obtain 500,000 doses of mpox vaccine for African countries dealing with an outbreak of the virus.

Radio France Internationale

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

DEA shutting down two offices in China even as agency struggles to stem flow of fentanyl chemicals

The U.S. Drug Enforcement Administration is closing two of its offices in China, a move that comes even as the agency struggles to disrupt the flow of precursor chemicals from the country that have fueled a fentanyl epidemic

Investors Business Daily

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Investors Business Daily

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

Investors Business Daily

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Investors Business Daily

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Kiplinger

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Investors Business Daily

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

International Business Times

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

Investors Business Daily

Moderna Crashes After Slashing Its R&D Budget, Issuing Light Guidance

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

152 stories

Gilead

132 stories

the Centers for Disease Control and Prevention

128 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.